id	sid	tid	token	lemma	pos
gra-372	1	1	introduction	introduction	NOUN
gra-372	1	2	hypertension	hypertension	NOUN
gra-372	1	3	is	be	AUX
gra-372	1	4	dened	dene	VERB
gra-372	1	5	as	as	ADP
gra-372	1	6	either	either	CCONJ
gra-372	1	7	a	a	DET
gra-372	1	8	sustained	sustained	ADJ
gra-372	1	9	systolic	systolic	ADJ
gra-372	1	10	blood	blood	NOUN
gra-372	1	11	pressure	pressure	NOUN
gra-372	1	12	of	of	ADP
gra-372	1	13	greater	great	ADJ
gra-372	1	14	than	than	ADP
gra-372	1	15	140	140	NUM
gra-372	1	16	mm	mm	NUM
gra-372	1	17	hg	hg	NOUN
gra-372	1	18	.	.	PROPN
gra-372	1	19	or	or	CCONJ
gra-372	1	20	a	a	DET
gra-372	1	21	sustained	sustained	ADJ
gra-372	1	22	diastolic	diastolic	NOUN
gra-372	1	23	blood	blood	NOUN
gra-372	1	24	pressure	pressure	NOUN
gra-372	1	25	of	of	ADP
gra-372	1	26	greater	great	ADJ
gra-372	1	27	than	than	ADP
gra-372	1	28	90	90	NUM
gra-372	1	29	mm	mm	NUM
gra-372	1	30	hg	hg	NOUN
gra-372	1	31	.	.	PUNCT
gra-372	2	1	according	accord	VERB
gra-372	2	2	to	to	ADP
gra-372	2	3	joint	joint	ADJ
gra-372	2	4	national	national	PROPN
gra-372	2	5	committee	committee	PROPN
gra-372	2	6	(	(	PUNCT
gra-372	2	7	jnc	jnc	PROPN
gra-372	2	8	viii	viii	PROPN
gra-372	2	9	)	)	PUNCT
gra-372	2	10	guidelines	guideline	NOUN
gra-372	2	11	on	on	ADP
gra-372	2	12	hypertension	hypertension	NOUN
gra-372	2	13	.	.	PUNCT
gra-372	3	1	it	it	PRON
gra-372	3	2	can	can	AUX
gra-372	3	3	lead	lead	VERB
gra-372	3	4	to	to	ADP
gra-372	3	5	coronary	coronary	ADJ
gra-372	3	6	artery	artery	NOUN
gra-372	3	7	disease	disease	NOUN
gra-372	3	8	cad	cad	PROPN
gra-372	3	9	,	,	PUNCT
gra-372	3	10	heart	heart	NOUN
gra-372	3	11	failure	failure	NOUN
gra-372	3	12	,	,	PUNCT
gra-372	3	13	stroke	stroke	NOUN
gra-372	3	14	,	,	PUNCT
gra-372	3	15	1renal	1renal	NUM
gra-372	3	16	failure	failure	NOUN
gra-372	3	17	and	and	CCONJ
gra-372	3	18	other	other	ADJ
gra-372	3	19	health	health	NOUN
gra-372	3	20	problems	problem	NOUN
gra-372	3	21	.	.	PUNCT
gra-372	4	1	among	among	ADP
gra-372	4	2	the	the	DET
gra-372	4	3	recommended	recommend	VERB
gra-372	4	4	rst	rst	PROPN
gra-372	4	5	l	l	PROPN
gra-372	4	6	ine	ine	PROPN
gra-372	4	7	agents	agent	NOUN
gra-372	4	8	for	for	ADP
gra-372	4	9	the	the	DET
gra-372	4	10	management	management	NOUN
gra-372	4	11	of	of	ADP
gra-372	4	12	hypertension	hypertension	NOUN
gra-372	4	13	,	,	PUNCT
gra-372	4	14	arbs	arb	NOUN
gra-372	4	15	are	be	AUX
gra-372	4	16	now	now	ADV
gra-372	4	17	widely	widely	ADV
gra-372	4	18	used	use	VERB
gra-372	4	19	2because	2because	NUM
gra-372	4	20	of	of	ADP
gra-372	4	21	their	their	PRON
gra-372	4	22	favorable	favorable	ADJ
gra-372	4	23	efcacy	efcacy	NOUN
gra-372	4	24	/	/	SYM
gra-372	4	25	tolerability	tolerability	NOUN
gra-372	4	26	proles	prole	NOUN
gra-372	4	27	.	.	PUNCT
gra-372	5	1	azilsartan	azilsartan	PROPN
gra-372	5	2	discovered	discover	VERB
gra-372	5	3	by	by	ADP
gra-372	5	4	japanese	japanese	ADJ
gra-372	5	5	scientists	scientist	NOUN
gra-372	5	6	by	by	ADP
gra-372	5	7	modifying	modify	VERB
gra-372	5	8	the	the	DET
gra-372	5	9	tetrazole	tetrazole	NOUN
gra-372	5	10	ring	ring	NOUN
gra-372	5	11	present	present	ADJ
gra-372	5	12	in	in	ADP
gra-372	5	13	candesartan	candesartan	PROPN
gra-372	5	14	.	.	PUNCT
gra-372	6	1	it	it	PRON
gra-372	6	2	blocks	block	VERB
gra-372	6	3	the	the	DET
gra-372	6	4	binding	binding	NOUN
gra-372	6	5	of	of	ADP
gra-372	6	6	angiotensin	angiotensin	NOUN
gra-372	6	7	-	-	PUNCT
gra-372	6	8	ii	ii	NOUN
gra-372	6	9	to	to	ADP
gra-372	6	10	its	its	PRON
gra-372	6	11	receptor	receptor	NOUN
gra-372	6	12	(	(	PUNCT
gra-372	6	13	at-1r	at-1r	PROPN
gra-372	6	14	)	)	PUNCT
gra-372	6	15	and	and	CCONJ
gra-372	6	16	inhibit	inhibit	VERB
gra-372	6	17	the	the	DET
gra-372	6	18	3	3	NUM
gra-372	6	19	-	-	SYM
gra-372	6	20	4vasoconstriction	4vasoconstriction	NUM
gra-372	6	21	effects	effect	NOUN
gra-372	6	22	of	of	ADP
gra-372	6	23	angiotensin	angiotensin	NOUN
gra-372	6	24	-	-	PUNCT
gra-372	6	25	ii	ii	NOUN
gra-372	6	26	.	.	PUNCT
gra-372	7	1	in	in	ADP
gra-372	7	2	an	an	DET
gra-372	7	3	in	in	ADP
gra-372	7	4	-	-	PUNCT
gra-372	7	5	vitro	vitro	X
gra-372	7	6	study	study	NOUN
gra-372	7	7	,	,	PUNCT
gra-372	7	8	azilsartan	azilsartan	PROPN
gra-372	7	9	was	be	AUX
gra-372	7	10	shown	show	VERB
gra-372	7	11	to	to	PART
gra-372	7	12	have	have	VERB
gra-372	7	13	a	a	DET
gra-372	7	14	higher	high	ADJ
gra-372	7	15	afnity	afnity	NOUN
gra-372	7	16	and	and	CCONJ
gra-372	7	17	slower	slow	ADJ
gra-372	7	18	dissociation	dissociation	NOUN
gra-372	7	19	from	from	ADP
gra-372	7	20	at1	at1	PROPN
gra-372	7	21	receptors	receptor	NOUN
gra-372	7	22	than	than	ADP
gra-372	7	23	other	other	ADJ
gra-372	7	24	arbs	arb	NOUN
gra-372	7	25	(	(	PUNCT
gra-372	7	26	as	as	ADP
gra-372	7	27	5	5	NUM
gra-372	7	28	olmesartan	olmesartan	ADJ
gra-372	7	29	,	,	PUNCT
gra-372	7	30	telmisartan	telmisartan	PROPN
gra-372	7	31	,	,	PUNCT
gra-372	7	32	valsartan	valsartan	PROPN
gra-372	7	33	and	and	CCONJ
gra-372	7	34	irbesartan	irbesartan	PROPN
gra-372	7	35	)	)	PUNCT
gra-372	7	36	.	.	PUNCT
gra-372	8	1	the	the	DET
gra-372	8	2	present	present	ADJ
gra-372	8	3	study	study	NOUN
gra-372	8	4	was	be	AUX
gra-372	8	5	designed	design	VERB
gra-372	8	6	to	to	PART
gra-372	8	7	compare	compare	VERB
gra-372	8	8	the	the	DET
gra-372	8	9	clinical	clinical	ADJ
gra-372	8	10	effectiveness	effectiveness	NOUN
gra-372	8	11	and	and	CCONJ
gra-372	8	12	tolerability	tolerability	NOUN
gra-372	8	13	of	of	ADP
gra-372	8	14	azilsartan	azilsartan	ADJ
gra-372	8	15	40	40	NUM
gra-372	8	16	mg	mg	PROPN
gra-372	8	17	od	od	PROPN
gra-372	8	18	with	with	ADP
gra-372	8	19	candesartan	candesartan	PROPN
gra-372	8	20	12	12	NUM
gra-372	8	21	mg	mg	NOUN
gra-372	8	22	od	od	NOUN
gra-372	8	23	in	in	ADP
gra-372	8	24	patients	patient	NOUN
gra-372	8	25	with	with	ADP
gra-372	8	26	grade	grade	NOUN
gra-372	8	27	1	1	NUM
gra-372	8	28	-	-	SYM
gra-372	8	29	2	2	NUM
gra-372	8	30	essential	essential	ADJ
gra-372	8	31	hypertension	hypertension	NOUN
gra-372	8	32	.	.	PUNCT
gra-372	9	1	materials	material	NOUN
gra-372	9	2	and	and	CCONJ
gra-372	9	3	methods	method	NOUN
gra-372	9	4	this	this	PRON
gra-372	9	5	was	be	AUX
gra-372	9	6	a	a	DET
gra-372	9	7	prospective	prospective	ADJ
gra-372	9	8	,	,	PUNCT
gra-372	9	9	randomized	randomized	ADJ
gra-372	9	10	study	study	NOUN
gra-372	9	11	carried	carry	VERB
gra-372	9	12	out	out	ADP
gra-372	9	13	in	in	ADP
gra-372	9	14	department	department	NOUN
gra-372	9	15	of	of	ADP
gra-372	9	16	pharmacology	pharmacology	NOUN
gra-372	9	17	and	and	CCONJ
gra-372	9	18	department	department	NOUN
gra-372	9	19	of	of	ADP
gra-372	9	20	medicine	medicine	NOUN
gra-372	9	21	,	,	PUNCT
gra-372	9	22	n.m.c	n.m.c	ADV
gra-372	9	23	patna	patna	PROPN
gra-372	9	24	between	between	ADP
gra-372	9	25	january	january	PROPN
gra-372	9	26	2019	2019	NUM
gra-372	9	27	to	to	ADP
gra-372	9	28	march	march	PROPN
gra-372	9	29	2019	2019	NUM
gra-372	9	30	.	.	PUNCT
gra-372	10	1	inclusion	inclusion	NOUN
gra-372	10	2	criteria	criterion	NOUN
gra-372	10	3	:	:	PUNCT
gra-372	10	4	patients	patient	NOUN
gra-372	10	5	of	of	ADP
gra-372	10	6	either	either	DET
gra-372	10	7	sex	sex	NOUN
gra-372	10	8	with	with	ADP
gra-372	10	9	age	age	NOUN
gra-372	10	10	>	>	SYM
gra-372	10	11	20	20	NUM
gra-372	10	12	years	year	NOUN
gra-372	10	13	with	with	ADP
gra-372	10	14	blood	blood	NOUN
gra-372	10	15	pressure	pressure	NOUN
gra-372	10	16	of	of	ADP
gra-372	10	17	>	>	X
gra-372	10	18	140/90	140/90	NUM
gra-372	10	19	mmhg	mmhg	NOUN
gra-372	10	20	.	.	PUNCT
gra-372	11	1	were	be	AUX
gra-372	11	2	included	include	VERB
gra-372	11	3	in	in	ADP
gra-372	11	4	the	the	DET
gra-372	11	5	study	study	NOUN
gra-372	11	6	.	.	PUNCT
gra-372	12	1	exclusion	exclusion	NOUN
gra-372	12	2	criteria	criterion	NOUN
gra-372	12	3	:	:	PUNCT
gra-372	13	1	severe	severe	ADJ
gra-372	13	2	hyper	hyper	ADJ
gra-372	13	3	tens	ten	NOUN
gra-372	13	4	ion	ion	NOUN
gra-372	13	5	w	w	NOUN
gra-372	14	1	i	i	PRON
gra-372	15	1	th	th	X
gra-372	15	2	b	b	X
gra-372	15	3	.p	.p	PROPN
gra-372	15	4	>	>	X
gra-372	15	5	180	180	NUM
gra-372	15	6	/110	/110	ADJ
gra-372	15	7	mmhg	mmhg	NOUN
gra-372	15	8	,	,	PUNCT
gra-372	15	9	hypersensitivity	hypersensitivity	NOUN
gra-372	15	10	to	to	PART
gra-372	15	11	arbs	arbs	X
gra-372	15	12	,	,	PUNCT
gra-372	15	13	secondary	secondary	ADJ
gra-372	15	14	hypertension	hypertension	NOUN
gra-372	15	15	,	,	PUNCT
gra-372	15	16	presence	presence	NOUN
gra-372	15	17	of	of	ADP
gra-372	15	18	cardiovascular	cardiovascular	ADJ
gra-372	15	19	disease	disease	NOUN
gra-372	15	20	(	(	PUNCT
gra-372	15	21	cvd	cvd	PROPN
gra-372	15	22	)	)	PUNCT
gra-372	15	23	,	,	PUNCT
gra-372	15	24	cardiac	cardiac	ADJ
gra-372	15	25	arrhythmias	arrhythmia	NOUN
gra-372	15	26	signicant	signicant	ADJ
gra-372	15	27	hepatic	hepatic	ADJ
gra-372	15	28	or	or	CCONJ
gra-372	15	29	renal	renal	ADJ
gra-372	15	30	disease	disease	NOUN
gra-372	15	31	,	,	PUNCT
gra-372	15	32	pregnant	pregnant	ADJ
gra-372	15	33	and	and	CCONJ
gra-372	15	34	lactating	lactate	VERB
gra-372	15	35	women	woman	NOUN
gra-372	15	36	.	.	PUNCT
gra-372	16	1	patients	patient	NOUN
gra-372	16	2	on	on	ADP
gra-372	16	3	antihypertensives	antihypertensive	NOUN
gra-372	16	4	,	,	PUNCT
gra-372	16	5	antianginal	antianginal	ADJ
gra-372	16	6	,	,	PUNCT
gra-372	16	7	antidepressant	antidepressant	ADJ
gra-372	16	8	,	,	PUNCT
gra-372	16	9	nsaids	nsaid	NOUN
gra-372	16	10	,	,	PUNCT
gra-372	16	11	glucocorticoids	glucocorticoid	NOUN
gra-372	16	12	,	,	PUNCT
gra-372	16	13	antiarrhythmic	antiarrhythmic	ADJ
gra-372	16	14	drugs	drug	NOUN
gra-372	16	15	.	.	PUNCT
gra-372	17	1	a	a	DET
gra-372	17	2	total	total	NOUN
gra-372	17	3	of	of	ADP
gra-372	17	4	80	80	NUM
gra-372	17	5	patients	patient	NOUN
gra-372	17	6	who	who	PRON
gra-372	17	7	fullled	fullle	VERB
gra-372	17	8	inclusion	inclusion	NOUN
gra-372	17	9	and	and	CCONJ
gra-372	17	10	exclusion	exclusion	NOUN
gra-372	17	11	criteria	criterion	NOUN
gra-372	17	12	and	and	CCONJ
gra-372	17	13	provided	provide	VERB
gra-372	17	14	informed	informed	ADJ
gra-372	17	15	consent	consent	NOUN
gra-372	17	16	were	be	AUX
gra-372	17	17	enrolled	enrol	VERB
gra-372	17	18	for	for	ADP
gra-372	17	19	participation	participation	NOUN
gra-372	17	20	in	in	ADP
gra-372	17	21	the	the	DET
gra-372	17	22	trial	trial	NOUN
gra-372	17	23	.	.	PUNCT
gra-372	18	1	sitting	sit	VERB
gra-372	18	2	b.p	b.p	PROPN
gra-372	18	3	was	be	AUX
gra-372	18	4	measured	measure	VERB
gra-372	18	5	3	3	NUM
gra-372	18	6	times	time	NOUN
gra-372	18	7	at	at	ADP
gra-372	18	8	1	1	NUM
gra-372	18	9	or	or	CCONJ
gra-372	18	10	2	2	NUM
gra-372	18	11	-	-	PUNCT
gra-372	18	12	min	min	NOUN
gra-372	18	13	interval	interval	NOUN
gra-372	18	14	using	use	VERB
gra-372	18	15	mercury	mercury	NOUN
gra-372	18	16	sphygmomanometer	sphygmomanometer	NOUN
gra-372	18	17	.	.	PUNCT
gra-372	19	1	then	then	ADV
gra-372	19	2	demographic	demographic	ADJ
gra-372	19	3	data	datum	NOUN
gra-372	19	4	were	be	AUX
gra-372	19	5	recorded	record	VERB
gra-372	19	6	.	.	PUNCT
gra-372	20	1	blood	blood	NOUN
gra-372	20	2	sugar	sugar	NOUN
gra-372	20	3	,	,	PUNCT
gra-372	20	4	urine	urine	NOUN
gra-372	20	5	analysis	analysis	NOUN
gra-372	20	6	,	,	PUNCT
gra-372	20	7	renal	renal	ADJ
gra-372	20	8	function	function	NOUN
gra-372	20	9	test	test	NOUN
gra-372	20	10	,	,	PUNCT
gra-372	20	11	liver	liver	NOUN
gra-372	20	12	function	function	NOUN
gra-372	20	13	test	test	NOUN
gra-372	20	14	and	and	CCONJ
gra-372	20	15	ecg	ecg	PROPN
gra-372	20	16	were	be	AUX
gra-372	20	17	assessed	assess	VERB
gra-372	20	18	.	.	PUNCT
gra-372	21	1	after	after	SCONJ
gra-372	21	2	this	this	DET
gra-372	21	3	patient	patient	NOUN
gra-372	21	4	were	be	AUX
gra-372	21	5	randomly	randomly	ADV
gra-372	21	6	divided	divide	VERB
gra-372	21	7	into	into	ADP
gra-372	21	8	2	2	NUM
gra-372	21	9	groups	group	NOUN
gra-372	21	10	.	.	PUNCT
gra-372	22	1	group	group	NOUN
gra-372	22	2	i	i	PRON
gra-372	22	3	received	receive	VERB
gra-372	22	4	azilsartan	azilsartan	ADJ
gra-372	22	5	40	40	NUM
gra-372	22	6	mg	mg	NOUN
gra-372	22	7	and	and	CCONJ
gra-372	22	8	group	group	PROPN
gra-372	22	9	ii	ii	PROPN
gra-372	22	10	received	receive	VERB
gra-372	22	11	candesartan	candesartan	PROPN
gra-372	22	12	12	12	NUM
gra-372	22	13	mg	mg	NUM
gra-372	22	14	and	and	CCONJ
gra-372	22	15	were	be	AUX
gra-372	22	16	instructed	instruct	VERB
gra-372	22	17	to	to	PART
gra-372	22	18	take	take	VERB
gra-372	22	19	the	the	DET
gra-372	22	20	tablet	tablet	NOUN
gra-372	22	21	orally	orally	ADV
gra-372	22	22	once	once	ADV
gra-372	22	23	a	a	DET
gra-372	22	24	day	day	NOUN
gra-372	22	25	in	in	ADP
gra-372	22	26	the	the	DET
gra-372	22	27	morning	morning	NOUN
gra-372	22	28	.	.	PUNCT
gra-372	23	1	assessment	assessment	NOUN
gra-372	23	2	of	of	ADP
gra-372	23	3	patients	patient	NOUN
gra-372	23	4	were	be	AUX
gra-372	23	5	done	do	VERB
gra-372	23	6	by	by	ADP
gra-372	23	7	measuring	measure	VERB
gra-372	23	8	sitting	sit	VERB
gra-372	23	9	b.p	b.p	PROPN
gra-372	23	10	,	,	PUNCT
gra-372	23	11	pulse	pulse	NOUN
gra-372	23	12	rate	rate	NOUN
gra-372	23	13	,	,	PUNCT
gra-372	23	14	physical	physical	ADJ
gra-372	23	15	examinations	examination	NOUN
gra-372	23	16	at	at	ADP
gra-372	23	17	2	2	NUM
gra-372	23	18	-	-	PUNCT
gra-372	23	19	week	week	NOUN
gra-372	23	20	,	,	PUNCT
gra-372	23	21	4	4	NUM
gra-372	23	22	week	week	NOUN
gra-372	23	23	and	and	CCONJ
gra-372	23	24	8	8	NUM
gra-372	23	25	week	week	NOUN
gra-372	23	26	prior	prior	ADV
gra-372	23	27	to	to	ADP
gra-372	23	28	taking	take	VERB
gra-372	23	29	their	their	PRON
gra-372	23	30	daily	daily	ADJ
gra-372	23	31	dose	dose	NOUN
gra-372	23	32	of	of	ADP
gra-372	23	33	medication	medication	NOUN
gra-372	23	34	.	.	PUNCT
gra-372	24	1	primary	primary	ADJ
gra-372	24	2	end	end	NOUN
gra-372	24	3	point	point	NOUN
gra-372	24	4	for	for	ADP
gra-372	24	5	assessing	assess	VERB
gra-372	24	6	efcacy	efcacy	NOUN
gra-372	24	7	was	be	AUX
gra-372	24	8	the	the	DET
gra-372	24	9	change	change	NOUN
gra-372	24	10	from	from	ADP
gra-372	24	11	baseline	baseline	NOUN
gra-372	24	12	in	in	ADP
gra-372	24	13	mean	mean	PROPN
gra-372	24	14	systolic	systolic	ADJ
gra-372	24	15	and	and	CCONJ
gra-372	24	16	diastolic	diastolic	NOUN
gra-372	24	17	b.p	b.p	PROPN
gra-372	24	18	after	after	ADP
gra-372	24	19	8	8	NUM
gra-372	24	20	weeks	week	NOUN
gra-372	24	21	of	of	ADP
gra-372	24	22	treatment	treatment	NOUN
gra-372	24	23	.	.	PUNCT
gra-372	25	1	regarding	regard	VERB
gra-372	25	2	adverse	adverse	ADJ
gra-372	25	3	events	event	NOUN
gra-372	25	4	,	,	PUNCT
gra-372	25	5	all	all	DET
gra-372	25	6	patients	patient	NOUN
gra-372	25	7	were	be	AUX
gra-372	25	8	queried	query	VERB
gra-372	25	9	at	at	ADP
gra-372	25	10	every	every	DET
gra-372	25	11	visit	visit	NOUN
gra-372	25	12	with	with	ADP
gra-372	25	13	non	non	ADJ
gra-372	25	14	-	-	ADJ
gra-372	25	15	leading	leading	ADJ
gra-372	25	16	questions	question	NOUN
gra-372	25	17	.	.	PUNCT
gra-372	26	1	statistical	statistical	ADJ
gra-372	26	2	analysisthe	analysisthe	DET
gra-372	26	3	difference	difference	NOUN
gra-372	26	4	of	of	ADP
gra-372	26	5	the	the	DET
gra-372	26	6	baseline	baseline	NOUN
gra-372	26	7	characteristics	characteristic	NOUN
gra-372	26	8	and	and	CCONJ
gra-372	26	9	change	change	NOUN
gra-372	26	10	in	in	ADP
gra-372	26	11	bp	bp	PROPN
gra-372	26	12	between	between	ADP
gra-372	26	13	groups	group	NOUN
gra-372	26	14	were	be	AUX
gra-372	26	15	compared	compare	VERB
gra-372	26	16	using	use	VERB
gra-372	26	17	an	an	DET
gra-372	26	18	unpaired	unpaired	ADJ
gra-372	26	19	t	t	NOUN
gra-372	26	20	test	test	NOUN
gra-372	26	21	.	.	PUNCT
gra-372	27	1	the	the	DET
gra-372	27	2	di	di	NOUN
gra-372	27	3	f	f	PROPN
gra-372	27	4	ference	ference	NOUN
gra-372	27	5	between	between	ADP
gra-372	27	6	values	value	NOUN
gra-372	27	7	before	before	ADV
gra-372	27	8	and	and	CCONJ
gra-372	27	9	af	af	PROPN
gra-372	27	10	ter	ter	X
gra-372	27	11	antihypertensive	antihypertensive	ADJ
gra-372	27	12	medication	medication	NOUN
gra-372	27	13	within	within	ADP
gra-372	27	14	the	the	DET
gra-372	27	15	same	same	ADJ
gra-372	27	16	group	group	NOUN
gra-372	27	17	were	be	AUX
gra-372	27	18	tested	test	VERB
gra-372	27	19	using	use	VERB
gra-372	27	20	a	a	DET
gra-372	27	21	paired	pair	VERB
gra-372	27	22	t	t	NOUN
gra-372	27	23	-	-	PUNCT
gra-372	27	24	test	test	NOUN
gra-372	27	25	.	.	PUNCT
gra-372	28	1	p	p	NOUN
gra-372	28	2	value	value	NOUN
gra-372	28	3	<	<	X
gra-372	28	4	0.05	0.05	NUM
gra-372	28	5	considered	consider	VERB
gra-372	28	6	statistically	statistically	ADV
gra-372	28	7	signicant	signicant	ADJ
gra-372	28	8	.	.	PUNCT
gra-372	29	1	result	result	VERB
gra-372	29	2	there	there	PRON
gra-372	29	3	were	be	VERB
gra-372	29	4	no	no	DET
gra-372	29	5	remarkable	remarkable	ADJ
gra-372	29	6	differences	difference	NOUN
gra-372	29	7	between	between	ADP
gra-372	29	8	the	the	DET
gra-372	29	9	treatment	treatment	NOUN
gra-372	29	10	groups	group	NOUN
gra-372	29	11	at	at	ADP
gra-372	29	12	baseline	baseline	NOUN
gra-372	29	13	for	for	ADP
gra-372	29	14	any	any	DET
gra-372	29	15	demographic	demographic	ADJ
gra-372	29	16	characteristics	characteristic	NOUN
gra-372	29	17	(	(	PUNCT
gra-372	29	18	table	table	NOUN
gra-372	29	19	no	no	NOUN
gra-372	29	20	.	.	NOUN
gra-372	29	21	1	1	NUM
gra-372	29	22	table	table	NOUN
gra-372	29	23	no	no	NOUN
gra-372	29	24	.	.	NOUN
gra-372	29	25	1	1	NUM
gra-372	29	26	:	:	PUNCT
gra-372	29	27	base	base	NOUN
gra-372	29	28	line	line	NOUN
gra-372	29	29	demographic	demographic	ADJ
gra-372	29	30	characteristics	characteristic	NOUN
gra-372	29	31	of	of	ADP
gra-372	29	32	enrolled	enrol	VERB
gra-372	29	33	hypertensive	hypertensive	ADJ
gra-372	29	34	patients	patient	NOUN
gra-372	29	35	comparative	comparative	ADJ
gra-372	29	36	study	study	NOUN
gra-372	29	37	of	of	ADP
gra-372	29	38	effectiveness	effectiveness	NOUN
gra-372	29	39	and	and	CCONJ
gra-372	29	40	safety	safety	NOUN
gra-372	29	41	of	of	ADP
gra-372	29	42	azilsartan	azilsartan	ADJ
gra-372	29	43	and	and	CCONJ
gra-372	29	44	candesartan	candesartan	VERB
gra-372	29	45	cilexetil	cilexetil	NOUN
gra-372	29	46	in	in	ADP
gra-372	29	47	patients	patient	NOUN
gra-372	29	48	with	with	ADP
gra-372	29	49	grade	grade	NOUN
gra-372	29	50	1	1	NUM
gra-372	29	51	-	-	SYM
gra-372	29	52	2	2	NUM
gra-372	29	53	essential	essential	ADJ
gra-372	29	54	hypertension	hypertension	NOUN
gra-372	29	55	in	in	ADP
gra-372	29	56	a	a	DET
gra-372	29	57	tertiary	tertiary	ADJ
gra-372	29	58	care	care	NOUN
gra-372	29	59	hospital	hospital	NOUN
gra-372	29	60	original	original	ADJ
gra-372	29	61	research	research	NOUN
gra-372	29	62	paper	paper	NOUN
gra-372	29	63	indu	indu	NOUN
gra-372	29	64	priyadarshini	priyadarshini	PROPN
gra-372	29	65	junior	junior	ADJ
gra-372	29	66	resident	resident	NOUN
gra-372	29	67	,	,	PUNCT
gra-372	29	68	department	department	NOUN
gra-372	29	69	of	of	ADP
gra-372	29	70	pharmacology	pharmacology	NOUN
gra-372	29	71	,	,	PUNCT
gra-372	29	72	nmch	nmch	NOUN
gra-372	29	73	,	,	PUNCT
gra-372	29	74	patnaprincipal	patnaprincipal	ADJ
gra-372	29	75	investigator	investigator	NOUN
gra-372	29	76	x	x	SYM
gra-372	29	77	43gjra	43gjra	PROPN
gra-372	29	78	global	global	ADJ
gra-372	29	79	journal	journal	PROPN
gra-372	29	80	for	for	ADP
gra-372	29	81	research	research	NOUN
gra-372	29	82	analysis	analysis	NOUN
gra-372	29	83	pharmacology	pharmacology	NOUN
gra-372	29	84	introduction	introduction	NOUN
gra-372	29	85	:	:	PUNCT
gra-372	29	86	hypertension	hypertension	NOUN
gra-372	29	87	is	be	AUX
gra-372	29	88	dened	dene	VERB
gra-372	29	89	as	as	ADP
gra-372	29	90	either	either	CCONJ
gra-372	29	91	a	a	DET
gra-372	29	92	sustained	sustained	ADJ
gra-372	29	93	systolic	systolic	ADJ
gra-372	29	94	blood	blood	NOUN
gra-372	29	95	pressure	pressure	NOUN
gra-372	29	96	of	of	ADP
gra-372	29	97	greater	great	ADJ
gra-372	29	98	than	than	ADP
gra-372	29	99	140	140	NUM
gra-372	29	100	mm	mm	NUM
gra-372	29	101	hg	hg	NOUN
gra-372	29	102	or	or	CCONJ
gra-372	29	103	a	a	DET
gra-372	29	104	sustained	sustained	ADJ
gra-372	29	105	diastolic	diastolic	NOUN
gra-372	29	106	blood	blood	NOUN
gra-372	29	107	pressure	pressure	NOUN
gra-372	29	108	of	of	ADP
gra-372	29	109	greater	great	ADJ
gra-372	29	110	than	than	ADP
gra-372	29	111	90	90	NUM
gra-372	29	112	mm	mm	NUM
gra-372	29	113	hg	hg	NOUN
gra-372	29	114	.	.	PUNCT
gra-372	29	115	.	.	PUNCT
gra-372	30	1	it	it	PRON
gra-372	30	2	can	can	AUX
gra-372	30	3	lead	lead	VERB
gra-372	30	4	to	to	ADP
gra-372	30	5	coronary	coronary	ADJ
gra-372	30	6	artery	artery	NOUN
gra-372	30	7	disease	disease	NOUN
gra-372	30	8	(	(	PUNCT
gra-372	30	9	cad	cad	NOUN
gra-372	30	10	)	)	PUNCT
gra-372	30	11	,	,	PUNCT
gra-372	30	12	heart	heart	NOUN
gra-372	30	13	failure	failure	NOUN
gra-372	30	14	,	,	PUNCT
gra-372	30	15	stroke	stroke	NOUN
gra-372	30	16	,	,	PUNCT
gra-372	30	17	renal	renal	ADJ
gra-372	30	18	failure	failure	NOUN
gra-372	30	19	and	and	CCONJ
gra-372	30	20	other	other	ADJ
gra-372	30	21	health	health	NOUN
gra-372	30	22	problems	problem	NOUN
gra-372	30	23	.	.	PUNCT
gra-372	31	1	the	the	DET
gra-372	31	2	angiotensin	angiotensin	NOUN
gra-372	31	3	receptor	receptor	NOUN
gra-372	31	4	blockers	blocker	NOUN
gra-372	31	5	are	be	AUX
gra-372	31	6	effective	effective	ADJ
gra-372	31	7	antihypertensive	antihypertensive	ADJ
gra-372	31	8	agent	agent	NOUN
gra-372	31	9	with	with	ADP
gra-372	31	10	excellent	excellent	ADJ
gra-372	31	11	tolerability	tolerability	NOUN
gra-372	31	12	proles	prole	NOUN
gra-372	31	13	.	.	PUNCT
gra-372	32	1	the	the	DET
gra-372	32	2	present	present	ADJ
gra-372	32	3	study	study	NOUN
gra-372	32	4	was	be	AUX
gra-372	32	5	designed	design	VERB
gra-372	32	6	to	to	PART
gra-372	32	7	compare	compare	VERB
gra-372	32	8	the	the	DET
gra-372	32	9	clinical	clinical	ADJ
gra-372	32	10	effectiveness	effectiveness	NOUN
gra-372	32	11	and	and	CCONJ
gra-372	32	12	tolerability	tolerability	NOUN
gra-372	32	13	of	of	ADP
gra-372	32	14	azilsartan	azilsartan	ADJ
gra-372	32	15	40	40	NUM
gra-372	32	16	mg	mg	PROPN
gra-372	32	17	od	od	PROPN
gra-372	32	18	with	with	ADP
gra-372	32	19	candesartan	candesartan	PROPN
gra-372	32	20	12	12	NUM
gra-372	32	21	mg	mg	NOUN
gra-372	32	22	od	od	NOUN
gra-372	32	23	in	in	ADP
gra-372	32	24	patients	patient	NOUN
gra-372	32	25	with	with	ADP
gra-372	32	26	grade	grade	NOUN
gra-372	32	27	1	1	NUM
gra-372	32	28	-	-	SYM
gra-372	32	29	2	2	NUM
gra-372	32	30	essential	essential	ADJ
gra-372	32	31	hypertension	hypertension	NOUN
gra-372	32	32	.	.	PUNCT
gra-372	33	1	materials	material	NOUN
gra-372	33	2	and	and	CCONJ
gra-372	33	3	methods	method	NOUN
gra-372	33	4	:	:	PUNCT
gra-372	33	5	the	the	DET
gra-372	33	6	present	present	ADJ
gra-372	33	7	study	study	NOUN
gra-372	33	8	was	be	AUX
gra-372	33	9	a	a	DET
gra-372	33	10	randomized	randomized	ADJ
gra-372	33	11	study	study	NOUN
gra-372	33	12	in	in	ADP
gra-372	33	13	80	80	NUM
gra-372	33	14	eligible	eligible	ADJ
gra-372	33	15	patients	patient	NOUN
gra-372	33	16	comparing	compare	VERB
gra-372	33	17	the	the	DET
gra-372	33	18	effectiveness	effectiveness	NOUN
gra-372	33	19	and	and	CCONJ
gra-372	33	20	safety	safety	NOUN
gra-372	33	21	of	of	ADP
gra-372	33	22	azilsartan	azilsartan	ADJ
gra-372	33	23	40	40	NUM
gra-372	33	24	mg	mg	PROPN
gra-372	33	25	with	with	ADP
gra-372	33	26	candesartan	candesartan	PROPN
gra-372	33	27	12	12	NUM
gra-372	33	28	mg	mg	NOUN
gra-372	33	29	in	in	ADP
gra-372	33	30	patients	patient	NOUN
gra-372	33	31	with	with	ADP
gra-372	33	32	grade	grade	NOUN
gra-372	33	33	1	1	NUM
gra-372	33	34	or	or	CCONJ
gra-372	33	35	2	2	NUM
gra-372	33	36	essential	essential	ADJ
gra-372	33	37	hypertension	hypertension	NOUN
gra-372	33	38	.	.	PUNCT
gra-372	34	1	result	result	VERB
gra-372	34	2	signicantly	signicantly	ADV
gra-372	34	3	greater	great	ADJ
gra-372	34	4	reductions	reduction	NOUN
gra-372	34	5	in	in	ADP
gra-372	34	6	the	the	DET
gra-372	34	7	sitting	sit	VERB
gra-372	34	8	dbp	dbp	PROPN
gra-372	34	9	and	and	CCONJ
gra-372	34	10	sbp	sbp	PROPN
gra-372	34	11	were	be	AUX
gra-372	34	12	recorded	record	VERB
gra-372	34	13	in	in	ADP
gra-372	34	14	the	the	DET
gra-372	34	15	azilsartan	azilsartan	ADJ
gra-372	34	16	group	group	NOUN
gra-372	34	17	in	in	ADP
gra-372	34	18	comparison	comparison	NOUN
gra-372	34	19	with	with	ADP
gra-372	34	20	the	the	DET
gra-372	34	21	candesartan	candesartan	ADJ
gra-372	34	22	group	group	NOUN
gra-372	34	23	at	at	ADP
gra-372	34	24	2	2	NUM
gra-372	34	25	weeks	week	NOUN
gra-372	34	26	,	,	PUNCT
gra-372	34	27	4	4	NUM
gra-372	34	28	weeks	week	NOUN
gra-372	34	29	and	and	CCONJ
gra-372	34	30	8	8	NUM
gra-372	34	31	weeks	week	NOUN
gra-372	34	32	.	.	PUNCT
gra-372	35	1	(	(	PUNCT
gra-372	35	2	p	p	NOUN
gra-372	35	3	value<0.001	value<0.001	NOUN
gra-372	35	4	)	)	PUNCT
gra-372	35	5	.	.	PUNCT
gra-372	36	1	the	the	DET
gra-372	36	2	most	most	ADV
gra-372	36	3	common	common	ADJ
gra-372	36	4	adverse	adverse	ADJ
gra-372	36	5	effect	effect	NOUN
gra-372	36	6	occurring	occur	VERB
gra-372	36	7	in	in	ADP
gra-372	36	8	the	the	DET
gra-372	36	9	patients	patient	NOUN
gra-372	36	10	in	in	ADP
gra-372	36	11	azilsartan	azilsartan	ADJ
gra-372	36	12	as	as	ADV
gra-372	36	13	well	well	ADV
gra-372	36	14	as	as	ADP
gra-372	36	15	in	in	ADP
gra-372	36	16	candesartan	candesartan	PROPN
gra-372	36	17	were	be	AUX
gra-372	36	18	nasopharyngitis	nasopharyngitis	ADJ
gra-372	36	19	,	,	PUNCT
gra-372	36	20	upper	upper	ADJ
gra-372	36	21	rti	rti	PROPN
gra-372	36	22	and	and	CCONJ
gra-372	36	23	pharyngitis	pharyngitis	NOUN
gra-372	36	24	.	.	PUNCT
gra-372	37	1	hypotension	hypotension	NOUN
gra-372	37	2	related	relate	VERB
gra-372	37	3	adverse	adverse	ADJ
gra-372	37	4	effects	effect	NOUN
gra-372	37	5	such	such	ADJ
gra-372	37	6	as	as	ADP
gra-372	37	7	dizziness	dizziness	NOUN
gra-372	37	8	,	,	PUNCT
gra-372	37	9	syncope	syncope	NOUN
gra-372	37	10	,	,	PUNCT
gra-372	37	11	vertigo	vertigo	PROPN
gra-372	37	12	was	be	AUX
gra-372	37	13	reported	report	VERB
gra-372	37	14	in	in	ADP
gra-372	37	15	both	both	CCONJ
gra-372	37	16	the	the	DET
gra-372	37	17	drugs	drug	NOUN
gra-372	37	18	.	.	PUNCT
gra-372	38	1	conclusion	conclusion	NOUN
gra-372	38	2	:	:	PUNCT
gra-372	38	3	azilsartan	azilsartan	PROPN
gra-372	38	4	is	be	AUX
gra-372	38	5	more	more	ADV
gra-372	38	6	effective	effective	ADJ
gra-372	38	7	and	and	CCONJ
gra-372	38	8	safe	safe	ADJ
gra-372	38	9	blood	blood	NOUN
gra-372	38	10	pressure	pressure	NOUN
gra-372	38	11	lowering	lower	VERB
gra-372	38	12	drug	drug	NOUN
gra-372	38	13	as	as	ADP
gra-372	38	14	comparable	comparable	ADJ
gra-372	38	15	to	to	ADP
gra-372	38	16	that	that	PRON
gra-372	38	17	of	of	ADP
gra-372	38	18	candesartan	candesartan	PROPN
gra-372	38	19	.	.	PUNCT
gra-372	39	1	abstract	abstract	ADJ
gra-372	39	2	keywords	keyword	NOUN
gra-372	39	3	:	:	PUNCT
gra-372	39	4	blood	blood	NOUN
gra-372	39	5	pressure	pressure	NOUN
gra-372	39	6	,	,	PUNCT
gra-372	39	7	azilsartan	azilsartan	PROPN
gra-372	39	8	,	,	PUNCT
gra-372	39	9	candesartan	candesartan	PROPN
gra-372	39	10	volume-8	volume-8	NUM
gra-372	39	11	,	,	PUNCT
gra-372	39	12	issue-10	issue-10	NOUN
gra-372	39	13	,	,	PUNCT
gra-372	39	14	october-2019	october-2019	ADJ
gra-372	39	15	•	•	NUM
gra-372	39	16	print	print	NOUN
gra-372	39	17	issn	issn	PROPN
gra-372	39	18	no	no	NOUN
gra-372	39	19	.	.	PROPN
gra-372	40	1	2277	2277	NUM
gra-372	40	2	8160	8160	NUM
gra-372	40	3	•	•	NOUN
gra-372	40	4	doi	doi	NOUN
gra-372	40	5	:	:	PUNCT
gra-372	40	6	10.36106	10.36106	NUM
gra-372	40	7	/	/	SYM
gra-372	40	8	gjra	gjra	ADJ
gra-372	40	9	satish	satish	PROPN
gra-372	40	10	kumar	kumar	PROPN
gra-372	40	11	associate	associate	PROPN
gra-372	40	12	professor	professor	NOUN
gra-372	40	13	,	,	PUNCT
gra-372	40	14	department	department	NOUN
gra-372	40	15	of	of	ADP
gra-372	40	16	medicine	medicine	NOUN
gra-372	40	17	,	,	PUNCT
gra-372	40	18	nmch	nmch	NOUN
gra-372	40	19	,	,	PUNCT
gra-372	40	20	patna	patna	NOUN
gra-372	40	21	-	-	PUNCT
gra-372	40	22	co	co	NOUN
gra-372	40	23	investigator	investigator	PROPN
gra-372	40	24	nadia	nadia	PROPN
gra-372	40	25	az	az	PROPN
gra-372	40	26	zahra	zahra	PROPN
gra-372	40	27	*	*	PROPN
gra-372	40	28	junior	junior	ADJ
gra-372	40	29	resident	resident	ADJ
gra-372	40	30	department	department	PROPN
gra-372	40	31	of	of	ADP
gra-372	40	32	pharmacology	pharmacology	NOUN
gra-372	40	33	,	,	PUNCT
gra-372	40	34	nmch	nmch	NOUN
gra-372	40	35	,	,	PUNCT
gra-372	40	36	patna	patna	NOUN
gra-372	40	37	*	*	PUNCT
gra-372	40	38	corresponding	correspond	VERB
gra-372	40	39	author	author	NOUN
gra-372	40	40	azilsartan(40	azilsartan(40	VERB
gra-372	40	41	mg	mg	NUM
gra-372	40	42	)	)	PUNCT
gra-372	40	43	candesartan(12	candesartan(12	NOUN
gra-372	40	44	mg	mg	NOUN
gra-372	40	45	)	)	PUNCT
gra-372	40	46	no	no	NOUN
gra-372	40	47	of	of	ADP
gra-372	40	48	patients	patient	NOUN
gra-372	40	49	48	48	NUM
gra-372	40	50	32	32	NUM
gra-372	40	51	age	age	NOUN
gra-372	40	52	52	52	NUM
gra-372	40	53	±	±	NUM
gra-372	40	54	8.4	8.4	NUM
gra-372	40	55	51	51	NUM
gra-372	40	56	±	±	NUM
gra-372	40	57	9.55	9.55	NUM
gra-372	40	58	gender	gender	NOUN
gra-372	40	59	male	male	NOUN
gra-372	40	60	66.4	66.4	NUM
gra-372	40	61	65.2	65.2	NUM
gra-372	40	62	female	female	NOUN
gra-372	40	63	33.6	33.6	NUM
gra-372	40	64	34.8	34.8	NUM
gra-372	40	65	bmi	bmi	NOUN
gra-372	40	66	24	24	NUM
gra-372	40	67	±	±	NUM
gra-372	40	68	2.4	2.4	NUM
gra-372	40	69	23	23	NUM
gra-372	40	70	±	±	NUM
gra-372	40	71	3	3	NUM
gra-372	40	72	base	base	NOUN
gra-372	40	73	line	line	NOUN
gra-372	40	74	blood	blood	NOUN
gra-372	40	75	pressure	pressure	NOUN
gra-372	40	76	dbp	dbp	PROPN
gra-372	40	77	92	92	NUM
gra-372	40	78	±	±	NUM
gra-372	40	79	3.5	3.5	NUM
gra-372	40	80	92	92	NUM
gra-372	40	81	±	±	NUM
gra-372	40	82	3.3	3.3	NUM
gra-372	40	83	sbp	sbp	NOUN
gra-372	40	84	146	146	NUM
gra-372	40	85	±	±	NUM
gra-372	40	86	11.5	11.5	NUM
gra-372	40	87	145	145	NUM
gra-372	40	88	±	±	NUM
gra-372	40	89	12.8	12.8	NUM
gra-372	40	90	44	44	NUM
gra-372	40	91	x	x	SYM
gra-372	40	92	gjra	gjra	PROPN
gra-372	40	93	global	global	ADJ
gra-372	40	94	journal	journal	PROPN
gra-372	40	95	for	for	ADP
gra-372	40	96	research	research	NOUN
gra-372	40	97	analysis	analysis	NOUN
gra-372	40	98	table	table	NOUN
gra-372	40	99	no	no	DET
gra-372	40	100	2	2	NUM
gra-372	40	101	:	:	PUNCT
gra-372	40	102	change	change	NOUN
gra-372	40	103	in	in	ADP
gra-372	40	104	diastolic	diastolic	ADJ
gra-372	40	105	blood	blood	NOUN
gra-372	40	106	pressure	pressure	NOUN
gra-372	40	107	(	(	PUNCT
gra-372	40	108	∆dbp	∆dbp	NOUN
gra-372	40	109	)	)	PUNCT
gra-372	40	110	and	and	CCONJ
gra-372	40	111	systolic	systolic	ADJ
gra-372	40	112	blood	blood	NOUN
gra-372	40	113	pressure	pressure	NOUN
gra-372	40	114	(	(	PUNCT
gra-372	40	115	∆sbp	∆sbp	NOUN
gra-372	40	116	)	)	PUNCT
gra-372	40	117	after	after	ADP
gra-372	40	118	2,4	2,4	NUM
gra-372	40	119	and	and	CCONJ
gra-372	40	120	8	8	NUM
gra-372	40	121	weeks	week	NOUN
gra-372	40	122	the	the	DET
gra-372	40	123	mean	mean	ADJ
gra-372	40	124	change	change	NOUN
gra-372	40	125	from	from	ADP
gra-372	40	126	baseline	baseline	NOUN
gra-372	40	127	in	in	ADP
gra-372	40	128	sitting	sit	VERB
gra-372	40	129	dbp	dbp	PROPN
gra-372	40	130	at	at	ADP
gra-372	40	131	week	week	NOUN
gra-372	40	132	2	2	NUM
gra-372	40	133	(	(	PUNCT
gra-372	40	134	azilsartan	azilsartan	NOUN
gra-372	40	135	-9.8mmhg	-9.8mmhg	PROPN
gra-372	40	136	,	,	PUNCT
gra-372	40	137	candesartan	candesartan	NOUN
gra-372	40	138	-8.8mmhg	-8.8mmhg	PROPN
gra-372	40	139	)	)	PUNCT
gra-372	40	140	,	,	PUNCT
gra-372	40	141	both	both	CCONJ
gra-372	40	142	azilsartan	azilsartan	ADJ
gra-372	40	143	and	and	CCONJ
gra-372	40	144	candesartan	candesartan	PROPN
gra-372	40	145	produced	produce	VERB
gra-372	40	146	signicant	signicant	ADJ
gra-372	40	147	decrease	decrease	NOUN
gra-372	40	148	,	,	PUNCT
gra-372	40	149	the	the	DET
gra-372	40	150	mean	mean	ADJ
gra-372	40	151	change	change	NOUN
gra-372	40	152	from	from	ADP
gra-372	40	153	baseline	baseline	NOUN
gra-372	40	154	in	in	ADP
gra-372	40	155	sitting	sit	VERB
gra-372	40	156	sbp	sbp	NOUN
gra-372	40	157	at	at	ADP
gra-372	40	158	week	week	NOUN
gra-372	40	159	2	2	NUM
gra-372	40	160	(	(	PUNCT
gra-372	40	161	azilsartan-13.6mmhg	azilsartan-13.6mmhg	PROPN
gra-372	40	162	,	,	PUNCT
gra-372	40	163	candesartan	candesartan	NOUN
gra-372	40	164	-10.0mmhg	-10.0mmhg	PROPN
gra-372	40	165	)	)	PUNCT
gra-372	40	166	,	,	PUNCT
gra-372	40	167	both	both	CCONJ
gra-372	40	168	azilsartan	azilsartan	ADJ
gra-372	40	169	and	and	CCONJ
gra-372	40	170	candesartan	candesartan	PROPN
gra-372	40	171	produced	produce	VERB
gra-372	40	172	signicant	signicant	ADJ
gra-372	40	173	decrease	decrease	NOUN
gra-372	40	174	(	(	PUNCT
gra-372	40	175	p	p	X
gra-372	40	176	value<0.001).(table	value<0.001).(table	ADJ
gra-372	40	177	no	no	INTJ
gra-372	40	178	.	.	NOUN
gra-372	40	179	2	2	NUM
gra-372	40	180	)	)	PUNCT
gra-372	40	181	the	the	DET
gra-372	40	182	mean	mean	ADJ
gra-372	40	183	change	change	NOUN
gra-372	40	184	in	in	ADP
gra-372	40	185	sitting	sit	VERB
gra-372	40	186	dbp	dbp	PROPN
gra-372	40	187	at	at	ADP
gra-372	40	188	week	week	NOUN
gra-372	40	189	4	4	NUM
gra-372	40	190	was	be	AUX
gra-372	40	191	(	(	PUNCT
gra-372	40	192	azilsartan	azilsartan	ADJ
gra-372	40	193	11.6	11.6	NUM
gra-372	40	194	mmhg	mmhg	NOUN
gra-372	40	195	,	,	PUNCT
gra-372	40	196	candesartan	candesartan	PROPN
gra-372	40	197	-9.8mmhg	-9.8mmhg	PROPN
gra-372	40	198	)	)	PUNCT
gra-372	40	199	resulting	result	VERB
gra-372	40	200	in	in	ADP
gra-372	40	201	a	a	DET
gra-372	40	202	signicant	signicant	ADJ
gra-372	40	203	decrease	decrease	NOUN
gra-372	40	204	in	in	ADP
gra-372	40	205	the	the	DET
gra-372	40	206	azilsartan	azilsartan	ADJ
gra-372	40	207	group	group	NOUN
gra-372	40	208	compared	compare	VERB
gra-372	40	209	with	with	ADP
gra-372	40	210	the	the	DET
gra-372	40	211	candesartan	candesartan	ADJ
gra-372	40	212	group	group	NOUN
gra-372	40	213	(	(	PUNCT
gra-372	40	214	p	p	PROPN
gra-372	40	215	value<0.001	value<0.001	PROPN
gra-372	40	216	)	)	PUNCT
gra-372	40	217	,	,	PUNCT
gra-372	40	218	the	the	DET
gra-372	40	219	mean	mean	ADJ
gra-372	40	220	change	change	NOUN
gra-372	40	221	from	from	ADP
gra-372	40	222	baseline	baseline	NOUN
gra-372	40	223	in	in	ADP
gra-372	40	224	sitting	sit	VERB
gra-372	40	225	sbp	sbp	NOUN
gra-372	40	226	at	at	ADP
gra-372	40	227	week	week	NOUN
gra-372	40	228	4	4	NUM
gra-372	40	229	.	.	PUNCT
gra-372	41	1	(	(	PUNCT
gra-372	41	2	azilsartan	azilsartan	PROPN
gra-372	41	3	-13.8mmhg	-13.8mmhg	PROPN
gra-372	41	4	,	,	PUNCT
gra-372	41	5	candesartan	candesartan	PROPN
gra-372	41	6	-10.8mmhg	-10.8mmhg	PROPN
gra-372	41	7	)	)	PUNCT
gra-372	41	8	,	,	PUNCT
gra-372	41	9	both	both	CCONJ
gra-372	41	10	azilsartan	azilsartan	ADJ
gra-372	41	11	and	and	CCONJ
gra-372	41	12	candesartan	candesartan	PROPN
gra-372	41	13	produced	produce	VERB
gra-372	41	14	signicant	signicant	ADJ
gra-372	41	15	decreases	decrease	NOUN
gra-372	41	16	(	(	PUNCT
gra-372	41	17	p	p	DET
gra-372	41	18	value<0.001.(table	value<0.001.(table	PROPN
gra-372	41	19	no.2	no.2	PROPN
gra-372	41	20	)	)	PUNCT
gra-372	41	21	the	the	DET
gra-372	41	22	mean	mean	ADJ
gra-372	41	23	change	change	NOUN
gra-372	41	24	in	in	ADP
gra-372	41	25	sitting	sit	VERB
gra-372	41	26	dbp	dbp	PROPN
gra-372	41	27	at	at	ADP
gra-372	41	28	week	week	NOUN
gra-372	41	29	8	8	NUM
gra-372	41	30	was	be	AUX
gra-372	41	31	(	(	PUNCT
gra-372	41	32	azilsartan	azilsartan	ADJ
gra-372	41	33	12.3	12.3	NUM
gra-372	41	34	mmhg	mmhg	NOUN
gra-372	41	35	,	,	PUNCT
gra-372	41	36	candesartan	candesartan	PROPN
gra-372	41	37	-10.4mmhg	-10.4mmhg	PROPN
gra-372	41	38	)	)	PUNCT
gra-372	41	39	resulting	result	VERB
gra-372	41	40	in	in	ADP
gra-372	41	41	a	a	DET
gra-372	41	42	signicant	signicant	ADJ
gra-372	41	43	decrease	decrease	NOUN
gra-372	41	44	in	in	ADP
gra-372	41	45	the	the	DET
gra-372	41	46	azilsartan	azilsartan	ADJ
gra-372	41	47	group	group	NOUN
gra-372	41	48	compared	compare	VERB
gra-372	41	49	with	with	ADP
gra-372	41	50	the	the	DET
gra-372	41	51	candesartan	candesartan	ADJ
gra-372	41	52	group	group	NOUN
gra-372	41	53	(	(	PUNCT
gra-372	41	54	p	p	PROPN
gra-372	41	55	value<0.001	value<0.001	NOUN
gra-372	41	56	)	)	PUNCT
gra-372	41	57	the	the	DET
gra-372	41	58	mean	mean	ADJ
gra-372	41	59	change	change	NOUN
gra-372	41	60	from	from	ADP
gra-372	41	61	baseline	baseline	NOUN
gra-372	41	62	in	in	ADP
gra-372	41	63	sitting	sit	VERB
gra-372	41	64	sbp	sbp	NOUN
gra-372	41	65	at	at	ADP
gra-372	41	66	week	week	NOUN
gra-372	41	67	8	8	NUM
gra-372	41	68	.	.	PUNCT
gra-372	42	1	(	(	PUNCT
gra-372	42	2	azilsartan	azilsartan	PROPN
gra-372	42	3	-14.8mmhg	-14.8mmhg	PROPN
gra-372	42	4	,	,	PUNCT
gra-372	42	5	candesartan	candesartan	PROPN
gra-372	42	6	-11.0mmhg	-11.0mmhg	PROPN
gra-372	42	7	)	)	PUNCT
gra-372	42	8	,	,	PUNCT
gra-372	42	9	both	both	CCONJ
gra-372	42	10	azilsartan	azilsartan	ADJ
gra-372	42	11	and	and	CCONJ
gra-372	42	12	candesartan	candesartan	PROPN
gra-372	42	13	produced	produce	VERB
gra-372	42	14	signicant	signicant	ADJ
gra-372	42	15	decreases	decrease	NOUN
gra-372	42	16	(	(	PUNCT
gra-372	42	17	p	p	PRON
gra-372	42	18	value<0.001.(table	value<0.001.(table	PROPN
gra-372	42	19	no.2	no.2	PROPN
gra-372	42	20	)	)	PUNCT
gra-372	42	21	fig	fig	NOUN
gra-372	42	22	.	.	PUNCT
gra-372	43	1	1	1	NUM
gra-372	43	2	shows	show	NOUN
gra-372	43	3	,	,	PUNCT
gra-372	43	4	after	after	ADP
gra-372	43	5	2	2	NUM
gra-372	43	6	,	,	PUNCT
gra-372	43	7	4	4	NUM
gra-372	43	8	and	and	CCONJ
gra-372	43	9	8	8	NUM
gra-372	43	10	weeks	week	NOUN
gra-372	43	11	of	of	ADP
gra-372	43	12	treatment	treatment	NOUN
gra-372	43	13	change	change	NOUN
gra-372	43	14	in	in	ADP
gra-372	43	15	dbp	dbp	PROPN
gra-372	43	16	and	and	CCONJ
gra-372	43	17	sbp	sbp	PROPN
gra-372	43	18	with	with	ADP
gra-372	43	19	azilsartan	azilsartan	PROPN
gra-372	43	20	40	40	NUM
gra-372	43	21	mg	mg	NOUN
gra-372	43	22	and	and	CCONJ
gra-372	43	23	candesartan	candesartan	PROPN
gra-372	43	24	12	12	NUM
gra-372	43	25	mg	mg	NOUN
gra-372	43	26	.	.	PUNCT
gra-372	44	1	signicantly	signicantly	ADV
gra-372	44	2	greater	great	ADJ
gra-372	44	3	reductions	reduction	NOUN
gra-372	44	4	in	in	ADP
gra-372	44	5	the	the	DET
gra-372	44	6	sitting	sit	VERB
gra-372	44	7	dbp	dbp	PROPN
gra-372	44	8	and	and	CCONJ
gra-372	44	9	sbp	sbp	PROPN
gra-372	44	10	were	be	AUX
gra-372	44	11	recorded	record	VERB
gra-372	44	12	in	in	ADP
gra-372	44	13	the	the	DET
gra-372	44	14	azilsartan	azilsartan	ADJ
gra-372	44	15	group	group	NOUN
gra-372	44	16	in	in	ADP
gra-372	44	17	comparison	comparison	NOUN
gra-372	44	18	with	with	ADP
gra-372	44	19	the	the	DET
gra-372	44	20	candesartan	candesartan	ADJ
gra-372	44	21	group	group	NOUN
gra-372	44	22	at	at	ADV
gra-372	44	23	all	all	DET
gra-372	44	24	measurement	measurement	NOUN
gra-372	44	25	time	time	NOUN
gra-372	44	26	points	point	NOUN
gra-372	44	27	.	.	PUNCT
gra-372	45	1	the	the	DET
gra-372	45	2	most	most	ADV
gra-372	45	3	common	common	ADJ
gra-372	45	4	adverse	adverse	ADJ
gra-372	45	5	effect	effect	NOUN
gra-372	45	6	occurring	occur	VERB
gra-372	45	7	in	in	ADP
gra-372	45	8	both	both	CCONJ
gra-372	45	9	the	the	DET
gra-372	45	10	drug	drug	NOUN
gra-372	45	11	group	group	NOUN
gra-372	45	12	patients	patient	NOUN
gra-372	45	13	were	be	AUX
gra-372	45	14	nasopharyngitis	nasopharyngitis	ADJ
gra-372	45	15	,	,	PUNCT
gra-372	45	16	upper	upper	ADJ
gra-372	45	17	rti	rti	PROPN
gra-372	45	18	and	and	CCONJ
gra-372	45	19	pharyngitis	pharyngitis	NOUN
gra-372	45	20	.	.	PUNCT
gra-372	46	1	other	other	ADJ
gra-372	46	2	adverse	adverse	ADJ
gra-372	46	3	effects	effect	NOUN
gra-372	46	4	occurring	occur	VERB
gra-372	46	5	in	in	ADP
gra-372	46	6	3	3	NUM
gra-372	46	7	%	%	NOUN
gra-372	46	8	of	of	ADP
gra-372	46	9	the	the	DET
gra-372	46	10	patients	patient	NOUN
gra-372	46	11	in	in	ADP
gra-372	46	12	the	the	DET
gra-372	46	13	azilsartan	azilsartan	ADJ
gra-372	46	14	group	group	NOUN
gra-372	46	15	were	be	AUX
gra-372	46	16	rashes	rash	NOUN
gra-372	46	17	,	,	PUNCT
gra-372	46	18	and	and	CCONJ
gra-372	46	19	in	in	ADP
gra-372	46	20	3	3	NUM
gra-372	46	21	%	%	NOUN
gra-372	46	22	were	be	AUX
gra-372	46	23	hypotension	hypotension	NOUN
gra-372	46	24	related	relate	VERB
gra-372	46	25	events	event	NOUN
gra-372	46	26	(	(	PUNCT
gra-372	46	27	dizziness	dizziness	NOUN
gra-372	46	28	,	,	PUNCT
gra-372	46	29	syncope	syncope	NOUN
gra-372	46	30	,	,	PUNCT
gra-372	46	31	vertigo	vertigo	NOUN
gra-372	46	32	)	)	PUNCT
gra-372	46	33	,	,	PUNCT
gra-372	46	34	whereas	whereas	SCONJ
gra-372	46	35	in	in	ADP
gra-372	46	36	candesartan	candesartan	PROPN
gra-372	46	37	group	group	NOUN
gra-372	46	38	dizziness	dizziness	NOUN
gra-372	46	39	,	,	PUNCT
gra-372	46	40	postural	postural	ADJ
gra-372	46	41	syncope	syncope	NOUN
gra-372	46	42	and	and	CCONJ
gra-372	46	43	vertigo	vertigo	NOUN
gra-372	46	44	were	be	AUX
gra-372	46	45	observed	observe	VERB
gra-372	46	46	in	in	ADP
gra-372	46	47	nearly	nearly	ADV
gra-372	46	48	8	8	NUM
gra-372	46	49	%	%	NOUN
gra-372	46	50	.	.	PUNCT
gra-372	47	1	discussion	discussion	NOUN
gra-372	47	2	present	present	ADJ
gra-372	47	3	study	study	NOUN
gra-372	47	4	was	be	AUX
gra-372	47	5	conducted	conduct	VERB
gra-372	47	6	for	for	ADP
gra-372	47	7	comparing	compare	VERB
gra-372	47	8	the	the	DET
gra-372	47	9	effectiveness	effectiveness	NOUN
gra-372	47	10	and	and	CCONJ
gra-372	47	11	safety	safety	NOUN
gra-372	47	12	of	of	ADP
gra-372	47	13	azilsartan	azilsartan	ADJ
gra-372	47	14	40	40	NUM
gra-372	47	15	mg	mg	NOUN
gra-372	47	16	with	with	ADP
gra-372	47	17	that	that	PRON
gra-372	47	18	of	of	ADP
gra-372	47	19	candesartan	candesartan	PROPN
gra-372	47	20	12	12	NUM
gra-372	47	21	mg	mg	NOUN
gra-372	47	22	in	in	ADP
gra-372	47	23	grade	grade	NOUN
gra-372	47	24	1	1	NUM
gra-372	47	25	-	-	SYM
gra-372	47	26	2	2	NUM
gra-372	47	27	hypertensive	hypertensive	ADJ
gra-372	47	28	patients	patient	NOUN
gra-372	47	29	.	.	PUNCT
gra-372	48	1	azilsartan	azilsartan	ADJ
gra-372	48	2	a	a	DET
gra-372	48	3	newer	new	ADJ
gra-372	48	4	angiotensin	angiotensin	NOUN
gra-372	48	5	receptor	receptor	NOUN
gra-372	48	6	blocker	blocker	NOUN
gra-372	48	7	has	have	AUX
gra-372	48	8	shown	show	VERB
gra-372	48	9	cardiovascular	cardiovascular	ADJ
gra-372	48	10	benets	benets	PROPN
gra-372	48	11	of	of	ADP
gra-372	48	12	lowering	lower	VERB
gra-372	48	13	blood	blood	NOUN
gra-372	48	14	pressure	pressure	NOUN
gra-372	48	15	in	in	ADP
gra-372	48	16	preclinical	preclinical	ADJ
gra-372	48	17	as	as	ADV
gra-372	48	18	well	well	ADV
gra-372	48	19	as	as	ADP
gra-372	48	20	clinical	clinical	ADJ
gra-372	48	21	trials	trial	NOUN
gra-372	48	22	.	.	PUNCT
gra-372	49	1	fig	fig	NOUN
gra-372	49	2	.	.	PUNCT
gra-372	50	1	1change	1change	NUM
gra-372	50	2	in	in	ADP
gra-372	50	3	dbp	dbp	PROPN
gra-372	50	4	and	and	CCONJ
gra-372	50	5	sbp	sbp	PROPN
gra-372	50	6	after	after	ADP
gra-372	50	7	2,4	2,4	NUM
gra-372	50	8	and	and	CCONJ
gra-372	50	9	8	8	NUM
gra-372	50	10	weeks	week	NOUN
gra-372	50	11	of	of	ADP
gra-372	50	12	therapy	therapy	NOUN
gra-372	50	13	these	these	DET
gra-372	50	14	benets	benets	PROPN
gra-372	50	15	are	be	AUX
gra-372	50	16	due	due	ADJ
gra-372	50	17	to	to	ADP
gra-372	50	18	its	its	PRON
gra-372	50	19	property	property	NOUN
gra-372	50	20	of	of	ADP
gra-372	50	21	high	high	ADJ
gra-372	50	22	afnity	afnity	NOUN
gra-372	50	23	to	to	ADP
gra-372	50	24	and	and	CCONJ
gra-372	50	25	s	s	VERB
gra-372	50	26	low	low	ADJ
gra-372	50	27	d	d	PROPN
gra-372	50	28	issoc	issoc	PROPN
gra-372	50	29	ia	ia	PROPN
gra-372	50	30	t	t	PROPN
gra-372	50	31	ion	ion	NOUN
gra-372	50	32	f	f	PROPN
gra-372	50	33	rom	rom	NOUN
gra-372	50	34	at1r	at1r	PROPN
gra-372	50	35	.	.	PUNCT
gra-372	51	1	in	in	ADP
gra-372	51	2	c	c	NOUN
gra-372	51	3	l	l	NOUN
gra-372	51	4	in	in	ADP
gra-372	51	5	i	i	PRON
gra-372	51	6	ca	can	AUX
gra-372	51	7	l	l	PROPN
gra-372	51	8	t	t	PROPN
gra-372	51	9	r	r	X
gra-372	51	10	ia	ia	PROPN
gra-372	51	11	l	l	PROPN
gra-372	51	12	s	s	PART
gra-372	51	13	,	,	PUNCT
gra-372	51	14	antihypertensive	antihypertensive	ADJ
gra-372	51	15	therapy	therapy	NOUN
gra-372	51	16	has	have	AUX
gra-372	51	17	been	be	AUX
gra-372	51	18	associated	associate	VERB
gra-372	51	19	with	with	ADP
gra-372	51	20	reductions	reduction	NOUN
gra-372	51	21	in	in	ADP
gra-372	51	22	stroke	stroke	NOUN
gra-372	51	23	incidence	incidence	NOUN
gra-372	51	24	,	,	PUNCT
gra-372	51	25	myocardial	myocardial	ADJ
gra-372	51	26	infarction	infarction	NOUN
gra-372	51	27	(	(	PUNCT
gra-372	51	28	mi	mi	NOUN
gra-372	51	29	)	)	PUNCT
gra-372	51	30	and	and	CCONJ
gra-372	51	31	heart	heart	NOUN
gra-372	51	32	6failure	6failure	NOUN
gra-372	51	33	.	.	PUNCT
gra-372	52	1	in	in	ADP
gra-372	52	2	the	the	DET
gra-372	52	3	present	present	ADJ
gra-372	52	4	study	study	NOUN
gra-372	52	5	,	,	PUNCT
gra-372	52	6	we	we	PRON
gra-372	52	7	have	have	AUX
gra-372	52	8	observed	observe	VERB
gra-372	52	9	that	that	SCONJ
gra-372	52	10	both	both	CCONJ
gra-372	52	11	azilsartan	azilsartan	ADJ
gra-372	52	12	(	(	PUNCT
gra-372	52	13	40	40	NUM
gra-372	52	14	mg	mg	NOUN
gra-372	52	15	once	once	ADV
gra-372	52	16	daily	daily	ADV
gra-372	52	17	)	)	PUNCT
gra-372	52	18	and	and	CCONJ
gra-372	52	19	candesartan	candesartan	PROPN
gra-372	52	20	(	(	PUNCT
gra-372	52	21	12	12	NUM
gra-372	52	22	mg	mg	NOUN
gra-372	52	23	once	once	ADV
gra-372	52	24	daily	daily	ADV
gra-372	52	25	)	)	PUNCT
gra-372	52	26	are	be	AUX
gra-372	52	27	effective	effective	ADJ
gra-372	52	28	agents	agent	NOUN
gra-372	52	29	in	in	ADP
gra-372	52	30	reducing	reduce	VERB
gra-372	52	31	both	both	CCONJ
gra-372	52	32	systolic	systolic	ADJ
gra-372	52	33	and	and	CCONJ
gra-372	52	34	diastolic	diastolic	ADJ
gra-372	52	35	bp	bp	PROPN
gra-372	52	36	but	but	CCONJ
gra-372	52	37	azilsartan	azilsartan	PROPN
gra-372	52	38	(	(	PUNCT
gra-372	52	39	40	40	NUM
gra-372	52	40	mg	mg	NOUN
gra-372	52	41	od	od	NUM
gra-372	52	42	)	)	PUNCT
gra-372	52	43	provided	provide	VERB
gra-372	52	44	a	a	DET
gra-372	52	45	signicantly	signicantly	ADV
gra-372	52	46	greater	great	ADJ
gra-372	52	47	reduction	reduction	NOUN
gra-372	52	48	of	of	ADP
gra-372	52	49	bp	bp	PROPN
gra-372	52	50	than	than	SCONJ
gra-372	52	51	candesartan	candesartan	PROPN
gra-372	52	52	12	12	NUM
gra-372	52	53	mg	mg	PROPN
gra-372	52	54	od	od	NUM
gra-372	52	55	)	)	PUNCT
gra-372	52	56	in	in	ADP
gra-372	52	57	patients	patient	NOUN
gra-372	52	58	of	of	ADP
gra-372	52	59	grade	grade	NOUN
gra-372	52	60	1	1	NUM
gra-372	52	61	-	-	SYM
gra-372	52	62	2	2	NUM
gra-372	52	63	essential	essential	ADJ
gra-372	52	64	hypertension	hypertension	NOUN
gra-372	52	65	at	at	ADP
gra-372	52	66	all	all	DET
gra-372	52	67	time	time	NOUN
gra-372	52	68	points	point	NOUN
gra-372	52	69	from	from	ADP
gra-372	52	70	week	week	NOUN
gra-372	52	71	2	2	NUM
gra-372	52	72	to	to	PART
gra-372	52	73	8	8	NUM
gra-372	52	74	over	over	ADP
gra-372	52	75	the	the	DET
gra-372	52	76	treatment	treatment	NOUN
gra-372	52	77	period	period	NOUN
gra-372	52	78	.	.	PUNCT
gra-372	53	1	most	most	ADJ
gra-372	53	2	of	of	ADP
gra-372	53	3	the	the	DET
gra-372	53	4	adverse	adverse	ADJ
gra-372	53	5	effect	effect	NOUN
gra-372	53	6	were	be	AUX
gra-372	53	7	mild	mild	ADJ
gra-372	53	8	in	in	ADP
gra-372	53	9	severity	severity	NOUN
gra-372	53	10	,	,	PUNCT
gra-372	53	11	and	and	CCONJ
gra-372	53	12	the	the	DET
gra-372	53	13	most	most	ADV
gra-372	53	14	commonly	commonly	ADV
gra-372	53	15	reported	report	VERB
gra-372	53	16	events	event	NOUN
gra-372	53	17	wi	wi	PROPN
gra-372	53	18	th	th	PRON
gra-372	53	19	both	both	DET
gra-372	53	20	drugs	drug	NOUN
gra-372	53	21	were	be	AUX
gra-372	53	22	nasopharyngitis	nasopharyngitis	ADJ
gra-372	53	23	,	,	PUNCT
gra-372	53	24	upper	upper	ADJ
gra-372	53	25	respiratory	respiratory	ADJ
gra-372	53	26	tract	tract	NOUN
gra-372	53	27	inammation	inammation	NOUN
gra-372	53	28	and	and	CCONJ
gra-372	53	29	pharyngitis	pharyngitis	NOUN
gra-372	53	30	.	.	PUNCT
gra-372	54	1	there	there	PRON
gra-372	54	2	was	be	VERB
gra-372	54	3	a	a	DET
gra-372	54	4	slightly	slightly	ADV
gra-372	54	5	higher	high	ADJ
gra-372	54	6	incidence	incidence	NOUN
gra-372	54	7	of	of	ADP
gra-372	54	8	hypotension	hypotension	NOUN
gra-372	54	9	related	relate	VERB
gra-372	54	10	events	event	NOUN
gra-372	54	11	(	(	PUNCT
gra-372	54	12	dizziness	dizziness	NOUN
gra-372	54	13	,	,	PUNCT
gra-372	54	14	syncope	syncope	NOUN
gra-372	54	15	,	,	PUNCT
gra-372	54	16	vertigo	vertigo	NOUN
gra-372	54	17	)	)	PUNCT
gra-372	54	18	,	,	PUNCT
gra-372	54	19	with	with	ADP
gra-372	54	20	candesartan	candesartan	PROPN
gra-372	54	21	(	(	PUNCT
gra-372	54	22	8	8	NUM
gra-372	54	23	%	%	NOUN
gra-372	54	24	)	)	PUNCT
gra-372	54	25	than	than	ADP
gra-372	54	26	with	with	ADP
gra-372	54	27	azilsartan(3%).earlier	azilsartan(3%).earli	ADJ
gra-372	54	28	clinical	clinical	ADJ
gra-372	54	29	trials	trial	NOUN
gra-372	54	30	conducted	conduct	VERB
gra-372	54	31	compared	compare	VERB
gra-372	54	32	azilsartan	azilsartan	ADV
gra-372	54	33	with	with	ADP
gra-372	54	34	other	other	ADJ
gra-372	54	35	arbs	arb	NOUN
gra-372	54	36	,	,	PUNCT
gra-372	54	37	have	have	AUX
gra-372	54	38	reported	report	VERB
gra-372	54	39	similar	similar	ADJ
gra-372	54	40	ndings	nding	NOUN
gra-372	54	41	to	to	ADP
gra-372	54	42	our	our	PRON
gra-372	54	43	study	study	NOUN
gra-372	54	44	.	.	PUNCT
gra-372	55	1	in	in	ADP
gra-372	55	2	a	a	DET
gra-372	55	3	multicenter	multicenter	NOUN
gra-372	55	4	randomized	randomize	VERB
gra-372	55	5	,	,	PUNCT
gra-372	55	6	double	double	ADJ
gra-372	55	7	blind	blind	ADJ
gra-372	55	8	study	study	NOUN
gra-372	55	9	that	that	SCONJ
gra-372	55	10	compared	compare	VERB
gra-372	55	11	azilsartan	azilsartan	ADV
gra-372	55	12	with	with	ADP
gra-372	55	13	olmesartan	olmesartan	PROPN
gra-372	55	14	us	us	PROPN
gra-372	55	15	patients	patient	NOUN
gra-372	55	16	with	with	ADP
gra-372	55	17	primary	primary	ADJ
gra-372	55	18	hypertension	hypertension	NOUN
gra-372	55	19	,	,	PUNCT
gra-372	55	20	azilsartan	azilsartan	PROPN
gra-372	55	21	was	be	AUX
gra-372	55	22	signicantly	signicantly	ADV
gra-372	55	23	effective	effective	ADJ
gra-372	55	24	in	in	ADP
gra-372	55	25	7lowering	7lowering	NUM
gra-372	55	26	mean	mean	NOUN
gra-372	55	27	24	24	NUM
gra-372	55	28	hr	hr	NOUN
gra-372	55	29	sbp	sbp	NOUN
gra-372	55	30	than	than	ADP
gra-372	55	31	olmesartan	olmesartan	PROPN
gra-372	55	32	.	.	PUNCT
gra-372	56	1	similarly	similarly	ADV
gra-372	56	2	,	,	PUNCT
gra-372	56	3	in	in	ADP
gra-372	56	4	a	a	DET
gra-372	56	5	multicenter	multicenter	NOUN
gra-372	56	6	,	,	PUNCT
gra-372	56	7	randomized	randomize	VERB
gra-372	56	8	,	,	PUNCT
gra-372	56	9	double	double	ADJ
gra-372	56	10	blind	blind	ADJ
gra-372	56	11	study	study	NOUN
gra-372	56	12	in	in	ADP
gra-372	56	13	patients	patient	NOUN
gra-372	56	14	with	with	ADP
gra-372	56	15	grade	grade	NOUN
gra-372	56	16	i	i	PROPN
gra-372	56	17	-	-	PUNCT
gra-372	56	18	ii	ii	PROPN
gra-372	56	19	hypertension	hypertension	NOUN
gra-372	56	20	conducted	conduct	VERB
gra-372	56	21	in	in	ADP
gra-372	56	22	latin	latin	ADJ
gra-372	56	23	american	american	ADJ
gra-372	56	24	countries	country	NOUN
gra-372	56	25	and	and	CCONJ
gra-372	56	26	the	the	DET
gra-372	56	27	usa	usa	PROPN
gra-372	56	28	,	,	PUNCT
gra-372	56	29	treatment	treatment	NOUN
gra-372	56	30	with	with	ADP
gra-372	56	31	azilsartan	azilsartan	PROPN
gra-372	56	32	was	be	AUX
gra-372	56	33	signicantly	signicantly	ADV
gra-372	56	34	more	more	ADV
gra-372	56	35	effective	effective	ADJ
gra-372	56	36	than	than	ADP
gra-372	56	37	valsartan	valsartan	PROPN
gra-372	56	38	and	and	CCONJ
gra-372	56	39	olmesartan	olmesartan	PROPN
gra-372	56	40	in	in	ADP
gra-372	56	41	lowering	lower	VERB
gra-372	56	42	mean	mean	PROPN
gra-372	56	43	24	24	NUM
gra-372	56	44	8hr	8hr	ADJ
gra-372	56	45	sbp	sbp	NOUN
gra-372	56	46	.	.	PUNCT
gra-372	57	1	in	in	ADP
gra-372	57	2	both	both	DET
gra-372	57	3	trials	trial	NOUN
gra-372	57	4	,	,	PUNCT
gra-372	57	5	safety	safety	NOUN
gra-372	57	6	prole	prole	PROPN
gra-372	57	7	of	of	ADP
gra-372	57	8	azilsartan	azilsartan	PROPN
gra-372	57	9	was	be	AUX
gra-372	57	10	like	like	ADP
gra-372	57	11	that	that	PRON
gra-372	57	12	of	of	ADP
gra-372	57	13	the	the	DET
gra-372	57	14	arbs	arb	NOUN
gra-372	57	15	and	and	CCONJ
gra-372	57	16	the	the	DET
gra-372	57	17	placebo	placebo	NOUN
gra-372	57	18	with	with	ADP
gra-372	57	19	which	which	PRON
gra-372	57	20	it	it	PRON
gra-372	57	21	was	be	AUX
gra-372	57	22	compared	compare	VERB
gra-372	57	23	.	.	PUNCT
gra-372	58	1	conclusion	conclusion	NOUN
gra-372	58	2	it	it	PRON
gra-372	58	3	may	may	AUX
gra-372	58	4	be	be	AUX
gra-372	58	5	concluded	conclude	VERB
gra-372	58	6	from	from	ADP
gra-372	58	7	the	the	DET
gra-372	58	8	present	present	ADJ
gra-372	58	9	study	study	NOUN
gra-372	58	10	that	that	PRON
gra-372	58	11	azilsartan	azilsartan	PROPN
gra-372	58	12	,	,	PUNCT
gra-372	58	13	a	a	DET
gra-372	58	14	newer	new	ADJ
gra-372	58	15	angiotensin	angiotensin	NOUN
gra-372	58	16	receptor	receptor	NOUN
gra-372	58	17	blocker	blocker	NOUN
gra-372	58	18	is	be	AUX
gra-372	58	19	an	an	DET
gra-372	58	20	effective	effective	ADJ
gra-372	58	21	and	and	CCONJ
gra-372	58	22	safe	safe	ADJ
gra-372	58	23	blood	blood	NOUN
gra-372	58	24	pressure	pressure	NOUN
gra-372	58	25	lowering	lower	VERB
gra-372	58	26	drug	drug	NOUN
gra-372	58	27	and	and	CCONJ
gra-372	58	28	is	be	AUX
gra-372	58	29	more	more	ADV
gra-372	58	30	effective	effective	ADJ
gra-372	58	31	than	than	ADP
gra-372	58	32	candesartan	candesartan	VERB
gra-372	58	33	with	with	ADP
gra-372	58	34	additional	additional	ADJ
gra-372	58	35	benet	benet	PROPN
gra-372	58	36	of	of	ADP
gra-372	58	37	lesser	less	ADJ
gra-372	58	38	side	side	NOUN
gra-372	58	39	effects	effect	NOUN
gra-372	58	40	and	and	CCONJ
gra-372	58	41	hence	hence	ADV
gra-372	58	42	can	can	AUX
gra-372	58	43	be	be	AUX
gra-372	58	44	safely	safely	ADV
gra-372	58	45	used	use	VERB
gra-372	58	46	in	in	ADP
gra-372	58	47	all	all	DET
gra-372	58	48	the	the	DET
gra-372	58	49	patients	patient	NOUN
gra-372	58	50	.	.	PUNCT
gra-372	59	1	references	reference	NOUN
gra-372	59	2	1	1	NUM
gra-372	59	3	.	.	PUNCT
gra-372	59	4	whalen	whalen	PROPN
gra-372	59	5	karen	karen	PROPN
gra-372	59	6	,	,	PUNCT
gra-372	59	7	richard	richard	PROPN
gra-372	59	8	finkel	finkel	PROPN
gra-372	59	9	,	,	PUNCT
gra-372	59	10	and	and	CCONJ
gra-372	59	11	thomas	thomas	PROPN
gra-372	59	12	a.	a.	NOUN
gra-372	59	13	panavelil	panavelil	PROPN
gra-372	59	14	.	.	PUNCT
gra-372	60	1	lippincots	lippincot	NOUN
gra-372	60	2	illustrated	illustrate	VERB
gra-372	60	3	reviews	review	NOUN
gra-372	60	4	:	:	PUNCT
gra-372	60	5	pharmacology	pharmacology	NOUN
gra-372	60	6	.	.	PUNCT
gra-372	61	1	sixth	sixth	ADJ
gra-372	61	2	edition	edition	NOUN
gra-372	61	3	.	.	PUNCT
gra-372	62	1	philadelphia	philadelphia	PROPN
gra-372	62	2	:	:	PUNCT
gra-372	62	3	wolters	wolters	PROPN
gra-372	62	4	kluwer	kluwer	PROPN
gra-372	62	5	,	,	PUNCT
gra-372	62	6	2015	2015	NUM
gra-372	62	7	pg.no:225	pg.no:225	NOUN
gra-372	62	8	.	.	PUNCT
gra-372	63	1	2	2	X
gra-372	63	2	.	.	X
gra-372	63	3	smith	smith	PROPN
gra-372	63	4	dh	dh	PROPN
gra-372	63	5	.	.	PUNCT
gra-372	64	1	comparison	comparison	NOUN
gra-372	64	2	of	of	ADP
gra-372	64	3	angiotensin	angiotensin	PROPN
gra-372	64	4	ii	ii	PROPN
gra-372	64	5	type	type	NOUN
gra-372	64	6	1	1	NUM
gra-372	64	7	receptor	receptor	NOUN
gra-372	64	8	antagonists	antagonist	NOUN
gra-372	64	9	in	in	ADP
gra-372	64	10	the	the	DET
gra-372	64	11	treatment	treatment	NOUN
gra-372	64	12	of	of	ADP
gra-372	64	13	essential	essential	ADJ
gra-372	64	14	hypertension	hypertension	NOUN
gra-372	64	15	.	.	PUNCT
gra-372	65	1	drugs	drug	NOUN
gra-372	65	2	.	.	PUNCT
gra-372	65	3	2008	2008	NUM
gra-372	65	4	;	;	PUNCT
gra-372	65	5	68:1207–1225	68:1207–1225	NUM
gra-372	65	6	.	.	PUNCT
gra-372	66	1	3	3	X
gra-372	66	2	.	.	X
gra-372	66	3	takeda	takeda	PROPN
gra-372	66	4	pharmaceuticals	pharmaceuticals	PROPN
gra-372	66	5	north	north	PROPN
gra-372	66	6	america	america	PROPN
gra-372	66	7	.	.	PUNCT
gra-372	67	1	edarbi	edarbi	NOUN
gra-372	67	2	prescribing	prescribe	VERB
gra-372	67	3	information	information	NOUN
gra-372	67	4	.	.	PUNCT
gra-372	68	1	2011	2011	NUM
gra-372	68	2	4	4	NUM
gra-372	68	3	.	.	X
gra-372	69	1	elliott	elliott	PROPN
gra-372	69	2	,	,	PUNCT
gra-372	69	3	wj	wj	PROPN
gra-372	69	4	,	,	PUNCT
gra-372	69	5	plauschinat	plauschinat	PROPN
gra-372	69	6	,	,	PUNCT
gra-372	69	7	ca	ca	NOUN
gra-372	69	8	,	,	PUNCT
gra-372	69	9	skrepnek	skrepnek	NOUN
gra-372	69	10	,	,	PUNCT
gra-372	69	11	gh	gh	PROPN
gra-372	69	12	,	,	PUNCT
gra-372	69	13	et	et	PROPN
gra-372	69	14	al	al	PROPN
gra-372	69	15	.	.	PROPN
gra-372	69	16	persistence	persistence	NOUN
gra-372	69	17	,	,	PUNCT
gra-372	69	18	adherence	adherence	NOUN
gra-372	69	19	,	,	PUNCT
gra-372	69	20	and	and	CCONJ
gra-372	69	21	risk	risk	NOUN
gra-372	69	22	of	of	ADP
gra-372	69	23	discontinuation	discontinuation	NOUN
gra-372	69	24	associated	associate	VERB
gra-372	69	25	with	with	ADP
gra-372	69	26	commonly	commonly	ADV
gra-372	69	27	prescribed	prescribe	VERB
gra-372	69	28	antihypertensive	antihypertensive	ADJ
gra-372	69	29	drug	drug	NOUN
gra-372	69	30	monotherapies	monotherapie	NOUN
gra-372	69	31	.	.	PUNCT
gra-372	70	1	j	j	PROPN
gra-372	70	2	am	be	AUX
gra-372	70	3	board	board	PROPN
gra-372	70	4	fam	fam	PROPN
gra-372	70	5	med	me	VERB
gra-372	70	6	.	.	PUNCT
gra-372	71	1	2007	2007	NUM
gra-372	71	2	;	;	PUNCT
gra-372	71	3	20(1	20(1	NUM
gra-372	71	4	):	):	PUNCT
gra-372	71	5	72	72	NUM
gra-372	71	6	–	–	PUNCT
gra-372	71	7	80	80	NUM
gra-372	71	8	.	.	X
gra-372	72	1	5	5	X
gra-372	72	2	.	.	X
gra-372	72	3	ojima	ojima	PROPN
gra-372	72	4	m	m	PROPN
gra-372	72	5	,	,	PUNCT
gra-372	72	6	igata	igata	PROPN
gra-372	72	7	h	h	NOUN
gra-372	72	8	,	,	PUNCT
gra-372	72	9	tanaka	tanaka	PROPN
gra-372	72	10	m	m	PROPN
gra-372	72	11	,	,	PUNCT
gra-372	72	12	sakamoto	sakamoto	PROPN
gra-372	72	13	h	h	PROPN
gra-372	72	14	,	,	PUNCT
gra-372	72	15	kuroita	kuroita	PROPN
gra-372	72	16	t	t	PROPN
gra-372	72	17	,	,	PUNCT
gra-372	72	18	kohara	kohara	PROPN
gra-372	72	19	y	y	PROPN
gra-372	72	20	,	,	PUNCT
gra-372	72	21	kubo	kubo	PROPN
gra-372	72	22	k	k	PROPN
gra-372	72	23	,	,	PUNCT
gra-372	72	24	fuse	fuse	NOUN
gra-372	72	25	h	h	NOUN
gra-372	72	26	,	,	PUNCT
gra-372	72	27	imura	imura	PROPN
gra-372	72	28	y	y	PROPN
gra-372	72	29	,	,	PUNCT
gra-372	72	30	kusumoto	kusumoto	PROPN
gra-372	72	31	k	k	PROPN
gra-372	72	32	,	,	PUNCT
gra-372	72	33	nagaya	nagaya	PROPN
gra-372	72	34	h.	h.	PROPN
gra-372	72	35	in	in	ADP
gra-372	72	36	vitro	vitro	X
gra-372	72	37	antagonistic	antagonistic	ADJ
gra-372	72	38	properties	property	NOUN
gra-372	72	39	of	of	ADP
gra-372	72	40	a	a	DET
gra-372	72	41	new	new	ADJ
gra-372	72	42	angiotensin	angiotensin	NOUN
gra-372	72	43	type	type	NOUN
gra-372	72	44	1	1	NUM
gra-372	72	45	receptor	receptor	NOUN
gra-372	72	46	blocker	blocker	NOUN
gra-372	72	47	,	,	PUNCT
gra-372	72	48	azilsartan	azilsartan	NOUN
gra-372	72	49	,	,	PUNCT
gra-372	72	50	in	in	ADP
gra-372	72	51	receptor	receptor	NOUN
gra-372	72	52	binding	bind	VERB
gra-372	72	53	and	and	CCONJ
gra-372	72	54	function	function	NOUN
gra-372	72	55	studies	study	NOUN
gra-372	72	56	.	.	PUNCT
gra-372	73	1	j	j	PROPN
gra-372	73	2	pharmacol	pharmacol	PROPN
gra-372	73	3	exp	exp	NOUN
gra-372	73	4	ther	ther	ADV
gra-372	73	5	.	.	PUNCT
gra-372	74	1	2011	2011	NUM
gra-372	74	2	;	;	PUNCT
gra-372	75	1	336:801–808	336:801–808	NUM
gra-372	75	2	.	.	PUNCT
gra-372	76	1	6	6	NUM
gra-372	76	2	.	.	X
gra-372	76	3	neal	neal	PROPN
gra-372	76	4	b	b	PROPN
gra-372	76	5	,	,	PUNCT
gra-372	76	6	macmahon	macmahon	PROPN
gra-372	76	7	s	s	PROPN
gra-372	76	8	,	,	PUNCT
gra-372	76	9	chapman	chapman	PROPN
gra-372	76	10	n.	n.	PROPN
gra-372	76	11	blood	blood	NOUN
gra-372	76	12	pressure	pressure	NOUN
gra-372	76	13	lowering	lower	VERB
gra-372	76	14	treatment	treatment	NOUN
gra-372	76	15	trialists	trialist	NOUN
gra-372	76	16	’	'	PUNCT
gra-372	76	17	collaboration	collaboration	NOUN
gra-372	76	18	.	.	PUNCT
gra-372	77	1	effects	effect	NOUN
gra-372	77	2	of	of	ADP
gra-372	77	3	ace	ace	ADJ
gra-372	77	4	inhibitors	inhibitor	NOUN
gra-372	77	5	,	,	PUNCT
gra-372	77	6	calcium	calcium	NOUN
gra-372	77	7	antagonists	antagonist	NOUN
gra-372	77	8	,	,	PUNCT
gra-372	77	9	and	and	CCONJ
gra-372	77	10	other	other	ADJ
gra-372	77	11	bloodpressure	bloodpressure	NOUN
gra-372	77	12	-	-	PUNCT
gra-372	77	13	lowering	lower	VERB
gra-372	77	14	drugs	drug	NOUN
gra-372	77	15	:	:	PUNCT
gra-372	77	16	results	result	NOUN
gra-372	77	17	of	of	ADP
gra-372	77	18	prospectively	prospectively	ADV
gra-372	77	19	designed	design	VERB
gra-372	77	20	overviews	overview	NOUN
gra-372	77	21	of	of	ADP
gra-372	77	22	randomised	randomised	ADJ
gra-372	77	23	trials	trial	NOUN
gra-372	77	24	.	.	PUNCT
gra-372	78	1	blood	blood	NOUN
gra-372	78	2	pressure	pressure	NOUN
gra-372	78	3	lowering	lower	VERB
gra-372	78	4	treatment	treatment	NOUN
gra-372	78	5	trialists	trialist	NOUN
gra-372	78	6	’	'	PUNCT
gra-372	78	7	collaboration	collaboration	NOUN
gra-372	78	8	.	.	PUNCT
gra-372	79	1	lancet	lancet	NOUN
gra-372	79	2	.	.	PUNCT
gra-372	80	1	2000	2000	NUM
gra-372	80	2	;	;	PUNCT
gra-372	80	3	356:1955	356:1955	X
gra-372	80	4	-	-	SYM
gra-372	80	5	64	64	NUM
gra-372	80	6	7	7	NUM
gra-372	80	7	.	.	PUNCT
gra-372	80	8	bakris	bakris	PROPN
gra-372	80	9	gl	gl	PROPN
gra-372	80	10	,	,	PUNCT
gra-372	80	11	sica	sica	PROPN
gra-372	81	1	d	d	PROPN
gra-372	81	2	,	,	PUNCT
gra-372	81	3	weber	weber	PROPN
gra-372	81	4	m	m	PROPN
gra-372	81	5	,	,	PUNCT
gra-372	81	6	white	white	PROPN
gra-372	81	7	wb	wb	PROPN
gra-372	81	8	,	,	PUNCT
gra-372	81	9	roberts	roberts	PROPN
gra-372	81	10	a	a	PROPN
gra-372	81	11	,	,	PUNCT
gra-372	81	12	perez	perez	PROPN
gra-372	81	13	a	a	PROPN
gra-372	81	14	,	,	PUNCT
gra-372	81	15	cao	cao	PROPN
gra-372	81	16	c	c	AUX
gra-372	81	17	,	,	PUNCT
gra-372	81	18	kupfer	kupfer	PROPN
gra-372	81	19	s.	s.	PROPN
gra-372	81	20	the	the	DET
gra-372	81	21	comparative	comparative	ADJ
gra-372	81	22	effects	effect	NOUN
gra-372	81	23	of	of	ADP
gra-372	81	24	azilsartan	azilsartan	ADJ
gra-372	81	25	medoxomil	medoxomil	NOUN
gra-372	81	26	and	and	CCONJ
gra-372	81	27	olmesartan	olmesartan	PROPN
gra-372	81	28	on	on	ADP
gra-372	81	29	ambulatory	ambulatory	ADJ
gra-372	81	30	and	and	CCONJ
gra-372	81	31	clinic	clinic	NOUN
gra-372	81	32	blood	blood	NOUN
gra-372	81	33	pressure	pressure	NOUN
gra-372	81	34	.	.	PUNCT
gra-372	82	1	j	j	PROPN
gra-372	82	2	clin	clin	PROPN
gra-372	82	3	hypertens	hyperten	NOUN
gra-372	82	4	.	.	PUNCT
gra-372	83	1	2011	2011	NUM
gra-372	83	2	;	;	PUNCT
gra-372	83	3	13:81–88	13:81–88	NUM
gra-372	83	4	.	.	PUNCT
gra-372	84	1	8	8	NUM
gra-372	84	2	.	.	X
gra-372	84	3	white	white	PROPN
gra-372	84	4	wb	wb	PROPN
gra-372	84	5	,	,	PUNCT
gra-372	84	6	weber	weber	PROPN
gra-372	84	7	ma	ma	PROPN
gra-372	84	8	,	,	PUNCT
gra-372	84	9	sica	sica	PROPN
gra-372	84	10	d	d	PROPN
gra-372	84	11	,	,	PUNCT
gra-372	84	12	bakris	bakris	PROPN
gra-372	84	13	gl	gl	PROPN
gra-372	84	14	,	,	PUNCT
gra-372	84	15	perez	perez	PROPN
gra-372	84	16	a	a	PROPN
gra-372	84	17	,	,	PUNCT
gra-372	84	18	cao	cao	PROPN
gra-372	84	19	c	c	AUX
gra-372	84	20	,	,	PUNCT
gra-372	84	21	kupfer	kupfer	PROPN
gra-372	84	22	s.	s.	PROPN
gra-372	84	23	effects	effect	NOUN
gra-372	84	24	of	of	ADP
gra-372	84	25	the	the	DET
gra-372	84	26	angiotensin	angiotensin	NOUN
gra-372	84	27	receptor	receptor	NOUN
gra-372	84	28	blocker	blocker	NOUN
gra-372	84	29	azilsartan	azilsartan	PROPN
gra-372	84	30	medoxomil	medoxomil	PROPN
gra-372	84	31	versus	versus	ADP
gra-372	84	32	olmesartan	olmesartan	PROPN
gra-372	84	33	and	and	CCONJ
gra-372	84	34	valsartan	valsartan	VERB
gra-372	84	35	on	on	ADP
gra-372	84	36	ambulatory	ambulatory	ADJ
gra-372	84	37	and	and	CCONJ
gra-372	84	38	clinic	clinic	NOUN
gra-372	84	39	blood	blood	NOUN
gra-372	84	40	pressure	pressure	NOUN
gra-372	84	41	in	in	ADP
gra-372	84	42	patients	patient	NOUN
gra-372	84	43	with	with	ADP
gra-372	84	44	stages	stage	NOUN
gra-372	84	45	1	1	NUM
gra-372	84	46	and	and	CCONJ
gra-372	84	47	2	2	NUM
gra-372	84	48	hypertension	hypertension	NOUN
gra-372	84	49	.	.	PUNCT
gra-372	85	1	hypertension	hypertension	NOUN
gra-372	85	2	.	.	PUNCT
gra-372	86	1	2011	2011	NUM
gra-372	86	2	;	;	PUNCT
gra-372	87	1	57:413–420	57:413–420	NUM
gra-372	87	2	.	.	PUNCT
gra-372	88	1	volume-8	volume-8	NUM
gra-372	88	2	,	,	PUNCT
gra-372	88	3	issue-10	issue-10	NOUN
gra-372	88	4	,	,	PUNCT
gra-372	88	5	october-2019	october-2019	ADJ
gra-372	88	6	•	•	NUM
gra-372	88	7	print	print	NOUN
gra-372	88	8	issn	issn	PROPN
gra-372	88	9	no	no	NOUN
gra-372	88	10	.	.	PROPN
gra-372	89	1	2277	2277	NUM
gra-372	89	2	8160	8160	NUM
gra-372	89	3	•	•	NOUN
gra-372	89	4	doi	doi	NOUN
gra-372	89	5	:	:	PUNCT
gra-372	89	6	10.36106	10.36106	NUM
gra-372	89	7	/	/	SYM
gra-372	89	8	gjra	gjra	ADJ
gra-372	89	9	azilsartan	azilsartan	NOUN
gra-372	89	10	(	(	PUNCT
gra-372	89	11	40	40	NUM
gra-372	89	12	mg	mg	NOUN
gra-372	89	13	)	)	PUNCT
gra-372	89	14	candesartan	candesartan	NOUN
gra-372	89	15	(	(	PUNCT
gra-372	89	16	12	12	NUM
gra-372	89	17	mg	mg	NOUN
gra-372	89	18	)	)	PUNCT
gra-372	89	19	2	2	NUM
gra-372	89	20	weeks	week	NOUN
gra-372	89	21	dbp	dbp	PROPN
gra-372	89	22	-9.8	-9.8	PROPN
gra-372	89	23	-8.8	-8.8	PROPN
gra-372	89	24	sbp	sbp	PROPN
gra-372	89	25	-13.6	-13.6	PROPN
gra-372	89	26	-10.0	-10.0	PROPN
gra-372	89	27	4	4	NUM
gra-372	89	28	weeks	week	NOUN
gra-372	89	29	dbp	dbp	PROPN
gra-372	89	30	-11.6	-11.6	PROPN
gra-372	89	31	-9.8	-9.8	PROPN
gra-372	89	32	sbp	sbp	PROPN
gra-372	89	33	-13.8	-13.8	NOUN
gra-372	89	34	-10.8	-10.8	NUM
gra-372	89	35	8	8	NUM
gra-372	89	36	weeks	week	NOUN
gra-372	89	37	dbp	dbp	PROPN
gra-372	89	38	-12.3	-12.3	PROPN
gra-372	89	39	-10.4	-10.4	NUM
gra-372	89	40	sbp	sbp	PROPN
gra-372	89	41	-14.8	-14.8	NUM
gra-372	89	42	-11.0	-11.0	PUNCT